RealTime Dynamix™: Bone and Mineral Metabolism US Q1 2019 Spotlight
RealTime Dynamix™: Bone and Mineral Metabolism US Q1 2019 Spotlight https://www.spherixglobalinsights.com/wp-content/uploads/2019/06/rtd-bone-q1-2019.pngDownload Report Spotlight Last month Spherix surveyed 201 US nephrologists about their management of secondary hyperparathyroidism, vitamin D insufficiency, and hyperphosphatemia in the dialysis and non-dialysis settings. See complimentary highlights from the Q2 2018 wave of RealTime Dynamix™: Bone and Mineral Metabolism US below. Contact […]
RealTime Dynamix™: Hyperkalemia US Q1 2019 Spotlight
RealTime Dynamix™: Hyperkalemia US Q1 2019 Spotlight https://www.spherixglobalinsights.com/wp-content/uploads/2019/06/RTD-HK-Q1-2019.pngDownload Report Spotlight Last week the FDA approved two products, Pfizer’s Retacrit and AstraZeneca’s Lokelma, both of which encountered lengthy regulatory delays. Retacrit is the first biosimilar ESA to enter the US market and will compete with Amgen’s Epogen and Aranesp and Roche’s Mircera. Lokelma (sodium zirconium cyclosilicate) […]
Pfizer’s Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market
Two-thirds of surveyed nephrologists do not expect their dialysis center to make Retacrit available for at least a year, if ever, according to the latest quarterly anemia report by Spherix Global Insights Download Report Overview EXTON, Pa., July 31, 2018 /PRNewswire/ — Plagued by regulatory delays, the FDA finally granted approval for Retacrit in May […]
Amgen’s Parsabiv Doubles in Most Recent Quarter But Strict Usage Guidelines from Large Dialysis Organizations, DaVita and Fresenius Medical Care, Stifle Potential
The majority of nephrologists intend to increase their use of Parsabiv in the next quarter, but access at dialysis units proves to be the greatest barrier, according to a new report released by Spherix Global Insights Download Report Overview EXTON, Pa., July 24, 2018 /PRNewswire/ – Nephrologists largely believe that an IV calcimimetic (e.g. Parsabiv) […]
Biosimilars in Nephrology: Pfizer’s Retacrit Gets FDA Clearance and Prepares to Challenge Amgen’s Anemia Franchise Head On
The latest quarterly anemia report from Spherix Global Insights indicates a receptive audience for biosimilar erythropoietin stimulating agents (ESAs), but also a pre-dialysis market looking for ESA-alternatives to anemia management. Download Report Overview EXTON, Pa., May 31, 2018 /PRNewswire/ — Following the receipt of two Complete Response Letters from the FDA related to manufacturing issues, […]
The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes its Debut with a New Iron Deficiency Anemia Indication in the Pre-Dialysis Setting
According to a recent report published by Spherix Global Insights, about one-third of the surveyed nephrologists (n=202) report the unmet need for new treatments for renal anemia is high. However, other many areas within nephrology, such as diabetic nephropathy and acute kidney injury, are considered a higher priority for new therapeutic options. Download Report Overview […]
Amgen’s Parsabiv Starts to Gain Ground in US Dialysis Market with the Nephrology User Base Expected to Climb from 20% to Over 80% Within the Next Six Months
In addition to converting patients from Amgen’s own oral calcimimetic, Sensipar, nephrologists anticipate an increase in the calcimimetic class overall as a result of Parsabiv’s introduction, according to a survey conducted by Spherix Global Insights last week. Download Report Overview EXTON, Pa., Feb. 1, 2018 /PRNewswire/ — It has been nearly a year since Amgen […]
Cardiologists Continue to Lag Nephrologists When It Comes to the Adoption of Vifor/Relypsa’s Veltassa for Hyperkalemia, but Prescribers in Both Specialties Report Mounting Market Access Pressure
At nearly two years post launch, close to 90% of nephrologists are using Veltassa compared to 61% of cardiologists and promotion could be a major factor in the difference between the specialties according to the latest quarterly update from Spherix Global Insights Download Report Overview (Cardiology) Download Report Overview (Nephrology) EXTON, Pa., Nov. 16, 2017 […]
In the CKD-MBD Market, OPKO’s Rayaldee Continues to Struggle While Keryx’s Auryxia Gains Momentum, According to Latest Quarterly Update from Spherix Global Insights
Amgen’s Parsabiv, having finally received a J-code effective January 2018, is poised for rapid uptake in the dialysis market, not only off-setting Amgen’s own Sensipar but expanding the calcimimetic-treated population overall Download Report Overview EXTON, Pa., Nov. 14, 2017 /PRNewswire/ — A survey of over 200 US nephrologists fielded in late September indicates that, while […]
The Renal Anemia Market is on the Cusp of Change Beginning with the FDA Approval of Keryx Biopharmaceutical’s Auryxia for the Treatment of Iron Deficiency Anemia (IDA) in Adults with Chronic Kidney Disease, Not on Dialysis (CKD-ND)
New indication should bolster sales of Auryxia according to the latest reports from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 7, 2017 /PRNewswire/ — Earlier today Keryx announced the second approval for Auryxia (ferric citrate) to treat iron deficiency anemia in patients with chronic kidney disease. It is the first oral iron product […]
